Retinitis pigmentosa is an eye disease in which there is damage to the retina. The retina is the layer of tissue at the back of the inner eye that converts light images to nerve signals and sends them to the brain.
Retinitis pigmentosa can run in families. The disorder can be caused by several genetic defects.
The cells controlling night vision (rods) are most likely to be affected. However, in some cases, retinal cone cells are damaged the most. The main sign of the disease is the presence of dark deposits in the retina.
The main risk factor is a family history of retinitis pigmentosa. It is a rare condition affecting about 1 in 4,000 people in the United States.
Symptoms often first appear in childhood. However, severe vision problems do not often develop before early adulthood.
- Decreased vision at night or in low light
- Loss of side (peripheral) vision, causing "tunnel vision"
- Loss of central vision (in advanced cases)
Exams and Tests
Tests to evaluate the retina:
- Color vision
- Exam of the retina by ophthalmoscopy after the pupils have been dilated
- Fluorescein angiography
- Intraocular pressure
- Measurement of the electrical activity in the retina (electroretinogram)
- Pupil reflex response
- Refraction test
- Retinal photography
- Side vision test (visual field test)
- Slit lamp examination
- Visual acuity
There is no effective treatment for this condition. Wearing sunglasses to protect the retina from ultraviolet light may help preserve vision.
Some studies suggest that treatment with antioxidants (such as high doses of vitamin A palmitate) may slow the disease. However, taking high doses of vitamin A can cause serious liver problems. The benefit of treatment has to be weighed against risks to the liver.
Clinical trials are in progress to assess new treatments for retinitis pigmentosa, including the use of DHA, which is an omega-3 fatty acid.
Other treatments, such as microchip implants into the retina that act like a microscopic video camera, are in the early stages of development. These treatments may be useful for treating blindness associated with RP and other serious eye conditions.
A vision specialist can help you adapt to vision loss. Make regular visits to an eye care specialist, who can detect cataracts or retinal swelling. Both of these problems can be treated.
The disorder will continue to progress slowly. Complete blindness is uncommon.
Peripheral and central loss of vision will occur over time.
People with retinitis pigmentosa often develop cataracts at an early age. They may also develop swelling of the retina (macular edema). Cataracts can be removed if they contribute to vision loss.
Many other conditions are similar to retinitis pigmentosa, including:
When to Contact a Medical Professional
Call your health care provider if you have problems with night vision or you develop other symptoms of this disorder.
Genetic counseling and testing may help determine whether your children are at risk for this disease.
Berson EL. Retinitis Pigmentosa and Allied Retinal Diseases. In: Tasman W, Jaeger EA, eds. Duane's Clinical Ophthalmology. 2013 ed. Philadelphia, PA: Lippincott, Williams & Wilkins: 2013:vol 3, chap 24.
Olitsky SE, Hug D, Plummer LS, Stass-Isern M. Disorders of the retina and vitreous. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, eds. Nelson Textbook of Pediatrics. 19th ed. Philadelphia, PA: Elsevier Saunders; 2011:chap 622.
Sieving PA, Caruso RC. Retinitis pigmentosa and related disorders. In: Yanoff M, Duker JS, eds. Ophthalmology. 3rd ed. Maryland Heights, MO: Elsevier Mosby; 2008:chap 6.10.
Stingl K, Bartz-Schmidt KU, Besch D, et al. Artificial vision with wirelessly powered subretinal electronic implant alpha-IMS. Proc Biol Sci. 2013;280(1757):1471-2954. PMID: 23427175 www.ncbi.nlm.nih.gov/pubmed/23427175.
Yanoff M, Cameron D. Diseases of the visual system. In: Goldman L, Schafer AI, eds. Goldman's Cecil Medicine. 24th ed. Philadelphia, PA: Elsevier Saunders; 2011:chap 431.
Reviewed By: Franklin W. Lusby, MD, Ophthalmologist, Lusby Vision Institute, La Jolla, CA. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team